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Background: Persistent symptoms including breathlessness, fatigue, and decreased 
exercise tolerance have been reported in patients after acute SARS- CoV- 2 infection. 
The biological mechanisms underlying this “long COVID” syndrome remain unknown. 
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1  |  INTRODUC TION
Recent studies have reported sustained symptoms in a signifi-
cant proportion of patients following acute SARS- CoV- 2 infec-
tion.1,2 Patients with this “long COVID” syndrome complain of 
persistent breathlessness, fatigue, and decreased exercise toler-
ance.2 Although the biological mechanisms underlying these ongo-
ing symptoms remain unknown, we recently reported that persistent 
increased D- dimer levels were present in approximately 25% of con-
valescent COVID- 19 patients up to 4 months following the appar-
ent resolution of their acute infection.3 Importantly, these increased 
D- dimers were seen in a significant number of both hospitalized 
and nonhospitalized COVID- 19 patients, respectively. Similarly, 
von Meijenfeldt et al also observed persistently elevated D- dimers 
in convalescent COVID- 19 patients at 4 months after hospital dis-
charge.4 Moreover, sustained prothrombotic changes in thrombin- 
generating capacity were also reported. Critically, however, the 
biological mechanisms underlying these persistent procoagulant ef-
fects following acute COVID- 19 remain poorly understood.
Postmortem studies in acute COVID- 19 have demon-
strated disseminated thrombosis throughout the pulmonary 
vasculature.5– 7 These thrombi are platelet- and fibrin- rich, and also 
contain neutrophils, neutrophil extracellular traps (NETs) and acti-
vated factor XII (FXII) that triggers the contact pathway.7,8 Current 
evidence suggests pulmonary thrombi in patients with severe 
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However, autopsy studies have highlighted the key roles played by pulmonary endo-
theliopathy and microvascular immunothrombosis in acute COVID- 19.
Objectives: To assess whether endothelial cell activation may be sustained in conva-
lescent COVID- 19 patients and contribute to long COVID pathogenesis.
Patients and Methods: Fifty patients were reviewed at a median of 68 days following 
SARS- CoV- 2 infection. In addition to clinical workup, acute phase markers, endothelial 
cell (EC) activation and NETosis parameters and thrombin generation were assessed.
Results: Thrombin generation assays revealed significantly shorter lag times 
(p < .0001, 95% CI −2.57 to −1.02 min), increased endogenous thrombin potential 
(p = .04, 95% CI 15– 416 nM/min), and peak thrombin (p < .0001, 95% CI 39– 93 nM) in 
convalescent COVID- 19 patients. These prothrombotic changes were independent of 
ongoing acute phase response or active NETosis. Importantly, EC biomarkers includ-
ing von Willebrand factor antigen (VWF:Ag), VWF propeptide (VWFpp), and factor 
VIII were significantly elevated in convalescent COVID- 19 compared with controls 
(p = .004, 95% CI 0.09– 0.57 IU/ml; p = .009, 95% CI 0.06– 0.5 IU/ml; p = .04, 95% 
CI 0.03– 0.44 IU/ml, respectively). In addition, plasma soluble thrombomodulin levels 
were significantly elevated in convalescent COVID- 19 (p = .02, 95% CI 0.01– 2.7 ng/
ml). Sustained endotheliopathy was more frequent in older, comorbid patients, and 
those requiring hospitalization. Finally, both plasma VWF:Ag and VWFpp levels cor-
related inversely with 6- min walk tests.
Conclusions: Collectively, our findings demonstrate that sustained endotheliopathy is 
common in convalescent COVID- 19 and raise the intriguing possibility that this may 
contribute to long COVID pathogenesis.
K E Y W O R D S
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Essentials
• Ongoing endotheliopathy is a common finding in con-
valescent COVID- 19 patients and is independent of the 
acute phase response.
• Plasma FVIII:C levels and thrombin generation are sig-
nificantly increased in convalescent COVID- 19 patients 
compared to healthy controls.
• Plasma VWF:Ag, VWFpp and sTM levels remain persis-
tently elevated in a proportion of patients following ap-
parent resolution of acute COVID- 19.
• Markers of endotheliopathy correlate inversely with 6- 
min walk tests in patients with ongoing symptoms after 
COVID- 19.
    |  3FOGARTY eT Al.
COVID- 19 likely arise in situ within the lungs, rather than being 
embolic in origin.7,9 Autopsy studies have consistently highlighted 
that marked pulmonary endotheliopathy is a characteristic fea-
ture of severe COVID- 19.5,7– 9 Consistent with these pathological 
findings, plasma markers of endothelial cell (EC) activation includ-
ing von Willebrand factor antigen (VWF:Ag),10– 15 VWF propeptide 
(VWFpp),16 and soluble thrombomodulin (sTM)10 are all markedly 
elevated in patients with severe COVID- 19. Importantly, these EC 
biomarkers also correlate with disease severity.10,12,16,17 Given the 
key roles of endotheliopathy and immunothrombosis in modulating 
the pathogenesis of acute SARS- CoV- 2,18 we hypothesized that per-
sistent EC activation might be important in modulating ongoing pro-
coagulant effects in convalescent COVID- 19 patients and thereby 
contribute to the pathogenesis underpinning long COVID.
2  |  METHODS
Consecutive adult patients were enrolled from the post- COVID- 19 
review clinic in St James's Hospital, Dublin, between May and 
September 2020. Patients were assessed at a minimum of 6 weeks 
following either symptom resolution in nonhospitalized patients 
or hospital discharge for those requiring admission.3 Informed 
written consent was obtained from all participants and ethical ap-
proval was obtained from the St James's Hospital Research Ethics 
Committee. A control group of nonhospitalized asymptomatic con-
trols (n = 17, mean age 47 ± 12 years) were also recruited. Plasma 
VWF:Ag, VWFpp, FVIII:C, and sTM were analyzed as previously 
described.16 Thrombin generation was performed in a Fluouroskan 
Ascent Fluorometer with Thrombinoscope software (Stago) using 
PPP Low reagent (1 pM tissue factor, 4 mM phospholipids) as be-
fore.19 Additionally, the release of extracellular DNA was measured 
using the fluorescent DNA- intercalating dye Sytox Green (Invitrogen) 
and DNase activity was assessed by an in vitro NET degradation 
assay.20,21 Activation of the contact factor pathway was evaluated 
by photometric measurement using conversion of the chromogenic 
substrate S- 2302 (Chromogenix).22 Clinical assessment at time of 
outpatient review included: chest x- ray, 6- min walk test (6MWT), 
measuring distance covered, lowest arterial oxygen saturation, and 
maximal exertion (using a Modified Borg Scale). Fatigue scores were 
assessed using the Chalder fatigue scale.23 Statistical analyses were 
performed using the Mann- Whitney U tests and the Spearman rank 
correlation in GraphPad Prism 9.0 (GraphPad Software, USA) with a 
p value of < .05 considered statistically significant.
3  |  RESULTS AND DISCUSSION
Fifty convalescent COVID- 19 patients (mean age 50 ± 17 years) 
were assessed at a median of 68 (interquartile range 61.3– 72) days 
following COVID- 19 symptom resolution or hospital discharge 
(Table S1). The majority of patients (37/50, 74%) required hospitali-
zation during their acute COVID- 19 illness and eight patients (16%) 
required intensive care unit admission. Median body mass index was 
28 kg/m2 (interquartile range 25– 32) and comorbidities were appar-
ent in 31 patients (31/50, 62%) (Table S1). All hospitalized patients 
received weight- and renally adjusted low molecular weight heparin 
prophylaxis during their inpatient stay. Conversely, nonhospitalized 
and discharged patients did not receive thromboprophylaxis and 
none of the cohort was on anticoagulation at time of convalescent 
clinic review.
In keeping with the recent report of von Meijenfeldt et al,4 signifi-
cantly enhanced thrombin generation was observed in convalescent 
COVID- 19 patients (Figure 1A– E and Figure S1A,B). Compared with 
healthy controls, lag times were significantly shorter in convalescent 
COVID- 19 patients (medians 6.2 min vs. 8.2 min, p < .0001, 95% 
CI −2.57 to −1.02) (Figure 1B). Additionally, endogenous thrombin 
potential and peak thrombin were both significantly higher in conva-
lescent COVID- 19 patients (median endogenous thrombin potential: 
1111 nM/min vs. 768 nM/min, p = .04, 95% CI 15– 416; median peak 
thrombin: 157 nM vs. 97 nM, p < .0001, 95% CI 39– 93) (Figure 1C– 
D). Convalescent COVID- 19 patients also demonstrated a shorter 
time to peak compared with controls (median 9.8 min vs. 13.8 min, 
p < .0001, 95% CI −4.8 to −2.7) (Figure 1E). To investigate whether 
ongoing contact pathway activation was responsible for the effects 
on thrombin generation, FXII activation was assessed. No significant 
differences in systemic FXIIa levels were seen between a subset of 
convalescent patients (n = 20) and controls (n = 17) (p = .16, 95% CI 
−0.15 to 0.03) (Figure S1C). Elevated plasma FVIII:C levels have previ-
ously been reported in patients with acute COVID- 19 and are known 
to influence thrombin generation. In the convalescent COVID- 19 pa-
tient cohort, plasma FVIII:C levels remained significantly increased 
compared with controls (median 1.53 IU/ml vs. 1.13 IU/ml; p = .04, 
95% CI 0.03– 0.44) with 14 (28%) patients having FVIII:C levels 
>1.5 IU/ml (Figure 1F). Notably, one patient with FVIII:C of 2.7 IU/
ml at follow- up 84 days postacute illness was later readmitted with 
pulmonary embolism. In addition, FVIII:C levels correlated with peak 
thrombin generation (p = .001) (Figure 1G). Together, these findings 
suggest that persistent increases in plasma FVIII levels contribute 
to ongoing increased thrombin generation potential in a significant 
proportion of convalescent COVID- 19 patients.
We next investigated the mechanism(s) responsible for the sus-
tained elevation in plasma FVIII:C levels in convalescent COVID- 19 
patients. Increased FVIII levels are associated with acute phase re-
sponses.24 However, in contrast to the significant elevation seen in 
FVIII:C levels in convalescent COVID- 19 patients, acute phase mark-
ers (including C- reactive protein, neutrophil and white cell counts, 
interleukin- 6, and sCD25 levels) had normalized in most patients 
(Table S1 and Figure S1D,E). Although NETosis has been implicated 
in acute COVID- 19 immunothrombosis and endotheliopathy,8,9 com-
parison of NETosis parameters in blood collected by peripheral veni-
puncture including DNase activity and extracellular DNA in a subset 
of convalescent patients and controls did not reveal any differences 
(median DNase activity convalescent COVID- 19 (n = 20): 22 792 AU 
vs. controls (n = 8): 18 835 AU; p = .53 95% CI −4554 to 9410 and 
median extracellular DNA convalescent COVID- 19 (n = 16): 0.37 μg/
4  |    FOGARTY eT Al.
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ml, vs. controls (n = 4): 0.37 μg/ml; p = .73, 95% CI −0.04 to 0.05) 
(Figure S1F– G).
In normal plasma, the majority of FVIII circulates in high- affinity 
complex with VWF. Moreover, both FVIII and VWF are predomi-
nantly synthesized within EC.25 We observed that plasma VWF:Ag 
levels were also significantly increased in convalescent COVID- 19 
patients compared with controls (median 1.1 IU/ml vs. 0.84 IU/ml; 
p = .004, 95% CI 0.09– 0.57) (Figure 1H). Marked interindividual vari-
ation was observed, with VWF:Ag levels ranging from 0.48 to 3.4 IU/
ml in convalescence. Notably, VWF:Ag levels above the upper limit 
of normal were observed in 15 patients (30%) with median VWF:Ag 
2.0 IU/ml in this subgroup (Figure 1H). In addition, FVIII:C levels 
also correlated strongly with VWF:Ag levels (r = 0.87; p < .0001) 
(Figure 1I). During posttranslational modification within ECs, an 
N- terminal 741 residue VWFpp is cleaved from each VWF mono-
mer. VWF:Ag and VWFpp are subsequently stored together within 
WPB and co- secreted in equimolar amounts following EC activation. 
We recently reported markedly elevated VWFpp levels in acute 
COVID- 19 and found that these levels correlated inversely with clin-
ical outcome.16 Interestingly, VWFpp levels were also significantly 
elevated in convalescent COVID- 19 patients compared with controls 
(p = .009, 95% CI 0.06– 0.5) (Figure 2A). Interpatient variation was 
again observed, with VWFpp levels being above the upper limit of 
normal in 10 patients (20%). Consistent with the concept of ongo-
ing endotheliopathy, VWFpp levels also correlated strongly with 
VWF:Ag levels (r = 0.87; p < .0001) (Figure 2B). Collectively, these 
data demonstrate that persistent endotheliopathy is a common find-
ing in convalescent COVID- 19 patients.
Thrombomodulin (TM) is an EC surface receptor that facilitates 
thrombin- induced activation of protein C on EC surfaces.26 Recently, 
Giri et al reported that TM plays a key role in maintaining EC qui-
escence.27 Of particular relevance, they showed that VWF expres-
sion and secretion was markedly increased in TM- deficient ECs. 
Interestingly, Goshua et al also demonstrated increased shedding of 
TM from EC in patients with acute COVID- 19. Furthermore, sTM lev-
els were found to represent an independent prognostic biomarker.10 
Given these data, we proceeded to investigate sTM levels in our 
cohort of convalescent COVID- 19 patients. We observed that sTM 
levels remained significantly elevated in convalescent COVID- 19 
compared with controls (median 5.3 vs. 4.1 ng/ml; p = .02, 95% CI 
0.01– 2.7) (Figure 2C). Interestingly, the highest sTM level (14.4 ng/ml) 
was observed in a patient who did not require hospitalization, sug-
gesting that sustained endotheliopathy during convalescence is not 
restricted to those who experienced severe COVID- 19. Consistent 
with the concept that loss of TM may be associated with reduced 
EC quiescence, we observed a significant correlation between sTM 
levels and plasma VWF:Ag levels (Figure 2D). Highest levels of all the 
EC activation parameters studied were consistently observed in the 
convalescent COVID cohort (Figure 2E).
To examine factors that influence sustained endotheliopathy fol-
lowing COVID- 19, clinical parameters including age, comorbidities, 
and severity of acute illness were assessed. On univariate analysis, 
plasma VWF:Ag, VWFpp, FVIII:C, and sTM were all significantly 
higher in patients who had required hospital admission during their 
acute COVID- 19; in patients aged ≥50 years and in patients with 
two or more comorbidities (Figure 2F and Figure S2A– C). These 
data are consistent with our previous observations that these same 
parameters also correlate with persistent elevated D- dimer levels 
in convalescent COVID- 19 patients.3 Finally, we investigated the 
relationship between markers of sustained endotheliopathy and 
clinical symptoms associated with long COVID syndrome in our co-
hort. Interestingly, significant inverse correlations were observed 
on univariate analysis between 6MWT distances vs. both VWF:Ag 
and VWFpp, respectively (Figure 2G– H). Given this association, 
we sought to further evaluate using multivariable linear regression 
analysis including the common confounders of age, sex, and severity 
of initial infection. Following adjustment, however, a significant re-
lationship between 6MWT distance and VWF:Ag (beta coefficient 
−4.4, 95% CI −65.5 to 56.7, p = .89) and VWFpp (beta coefficient 
−64.2, 95% CI −157.8 to 29.3, p = .17) was no longer seen.
Our study has some limitations. These include the small num-
ber of cases, the limited period after the acute infection, and the 
observational and retrospective design. In addition, the relation-
ship between clinical outcome measures such as the 6MWT may 
be confounded by old age and comorbidities. Finally, EC activation 
is not unique to COVID- 19. EC activation and dysfunction have 
also been described to play important roles in the pathogenesis of 
other severe viral illnesses. including influenza.28,29 However, spe-
cific differences in vascular perturbance between acute COVID- 19 
and influenza have also been described. Ackermann et al showed 
that at autopsy, alveolar capillary microthrombi were 9 times more 
prevalent in patients with COVID- 19 compared with patients with 
influenza.5 Moreover, new pulmonary vessel formation was also 
significantly higher in COVID- 19 patients, with prominent intus-
susceptive angiogenesis. In addition, Stals et al recently reported 
that thrombotic complications were significantly higher in hospi-
talized patients with acute COVID- 19 compared with influenza.30 
Collectively, these data suggest that are some similarities but also 
F I G U R E  1  Representative thrombin generation curves (A); each curve shows the mean of duplicate reactions from one individual's 
plasma. The quantitative parameters of (B) lag time, (C) endogenous thrombin potential (ETP), (D) peak thrombin, and (E) time to peak were 
derived from the thrombin generation curves, comparing convalescent COVID- 19 (n = 50) and healthy controls (n = 17). Comparison of 
EC activation parameters between convalescent COVID- 19 (n = 50) and healthy controls (n = 17) are shown, including (F) FVIII:C and (H) 
VWF:Ag. Data are presented as median and the interquartile range. Comparisons between groups were assessed by the Mann- Whitney U 
test. Dotted lines represent the upper and lower limits of the local normal range with results in the green shaded areas falling within the 
normal reference range. Correlations are shown between plasma levels of FVIII:C and (G) Peak thrombin and (I) VWF:Ag. Correlations were 
evaluated using the Spearman rank correlation test. (*p < .05, **p < .01, ****p < .0001). EC, endothelial cell; FVIII, factor FVIII; VWF:Ag, von 
Willebrand factor antigen
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important differences vis- a- vis pathogenesis, endotheliopathy 
and immunothrombosis between acute COVID- 19 and other acute 
viral infections. To better understand the potential translational 
significance of our findings, additional studies including “omics” 
and imaging that directly compare EC activation and dysfunction 
in convalescent COVID- 19 patients as opposed to patients recov-
ering from other types of severe viral illness will be essential.
In conclusion, our data demonstrate for the first time that sus-
tained EC activation is common up to 10 weeks following acute 
SARS- CoV- 2 infection. Importantly, this persistent endotheliopathy 
F I G U R E  2  Comparison of EC activation parameters between convalescent COVID- 19 (n = 50) and healthy controls (n = 17) including: 
(A) VWFpp and (C) sTM. Data are presented as median and the interquartile range. Comparisons between groups were assessed by the 
Mann- Whitney U test. Dotted lines represent the upper and lower limits of the local normal range with results in the green shaded areas 
falling within the normal reference range. Correlations are shown between plasma levels of (B) VWF:Ag vs. VWFpp and (D) VWF:Ag vs. sTM. 
(E) Heatmap visualization indicating EC marker levels detected in each subject (columns) for each protein (rows). (F) Convalescent VWF:Ag 
results are grouped according to whether acute infection was managed as an outpatient or inpatient; patients were aged ≥50 or <50 years 
and whether comorbidity counts were ≥2 or <2, respectively. Correlations are shown between 6- min walk test distance and plasma levels 
of (G) VWF:Ag and (H) VWFpp, respectively. Correlations were evaluated using the Spearman rank correlation test. (ns, not significant, 
*p < .05, **p < .01, ****p < .0001). EC, endothelial cell; VWF:Ag, von Willebrand factor antigen; VWFpp, von Willebrand factor propeptide
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appears to occur independently of ongoing acute phase response 
or NETosis and is associated with enhanced thrombin generation 
potential. We postulate that shedding of TM from EC may play a 
role in modulating the loss of normal EC quiescence. These findings 
are interesting given the critical role played by endotheliopathy in 
the pathogenesis of acute COVID- 19. However, further adequately 
powered clinical trials will be required to determine whether this 
sustained EC activation and coagulation activation has a role in (1) 
stratifying patients at increased risk of thrombotic events after res-
olution of acute SARS- CoV- 2 infection who may benefit from ex-
tended duration postdischarge thromboprophylaxis and/or (2) the 
pathogenesis of long COVID syndrome.
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